Agenus presents long-term survival data for botensilimab-balstilimab in MSS metastatic colorectal cancer at SITC 2026

Bitget2026/10/02 13:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Agenus disclosed two research posters on botensilimab with balstilimab accepted for SITC 2026, with presentations scheduled for Nov. 7.
One poster reviews long-term survivors in refractory MSS metastatic colorectal cancer treated with the regimen, aiming to clarify who benefits most.
A second poster reports preclinical translational findings combining the antibodies with MiNK’s agenT-797, showing tumor-cell killing in a liver-metastasis model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261002153709) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Agenus presents long-term survival data for botensilimab-balstilimab in MSS metastatic colorectal cancer at SITC 2026

You may also like

Crypto prices